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ventricular arrhythmias in a cohort with “unexplained” out-of-hospital cardiac arrest.Background Ventricular arrhythmias are an important cause of sudden unexpected death in the young. The role of MVP in sudden
unexpected death remains controversial.Methods Of 1,200 patients evaluated between July 2000 and December 2009 in the Mayo Clinic’s Long QT Syndrome/
Genetic Heart Rhythm Clinic, all 24 (16 women, median age 33.5 years) with idiopathic out-of-hospital cardiac
arrest (i.e., negative for ischemia, cardiomyopathy, and channelopathy) were reviewed.Results All 24 patients had implantable cardioverter-deﬁbrillators (ICDs). Out-of-hospital cardiac arrest was the sentinel
event in 22 (92%). Bileaﬂet MVP was found in 10 (42%). Compared with patients with normal mitral valves, patients
with bileaﬂet MVP: 1) were over-represented by women (9 of 10 [90%] vs. 7 of 14 [50%], p ¼ 0.04); 2) had a higher
prevalence of biphasic or inverted T waves (7 of 9 [77.8%] vs. 4 of 14 [29%], p ¼ 0.04); and 3) on Holter
interrogation had higher prevalence of ventricular bigeminy (9 of 9 [100%] vs. 1 of 10 [10%], p < 0.0001),
ventricular tachycardia (7 of 9 [78%] vs. 1 of 10 [10%], p ¼ 0.006), and premature ventricular contractions
originating from the outﬂow tract alternating with the papillary muscle or fascicular region (7 of 9 [78%] vs. 2 of
10 [20%], p ¼ 0.02). Over a median 1.8 years (range: 0.1 to 11.9 years) from ICD placement, 13 of 24 patients
(54%) received appropriate ventricular ﬁbrillation–terminating ICD shocks. Only bileaﬂet MVP was associated with
ventricular ﬁbrillation recurrences requiring ICD therapy on follow-up (logistic regression odds ratio: 7.2;
95% conﬁdence interval: 1.1 to 48; p ¼ 0.028).Conclusions The authors describe a “malignant” subset of patients with MVP who experienced life-threatening ventricular
arrhythmias. This phenotype is characterized by bileaﬂet MVP, female sex, and frequent complex ventricular ectopic
activity, including premature ventricular contractions of the outﬂow tract alternating with papillary muscle or
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, 2012; revised manuscript received January 16,of patients who experience out-of-hospital cardiac arrest
(OHCA) but lack clinical evidence of either ischemic
cardiomyopathy or nonischemic structural or electrical
cardiomyopathies. Identifying this subset of patients with
unexplained OHCA is challenging (1).
In this context, the role of mitral valve prolapse (MVP) in
sudden unexpected death (SUD) and OHCA remains
controversial. MVP has been reported as the only cardiac
abnormality at autopsy in certain apparently healthy subjects
who died suddenly or were resuscitated successfully from
OHCA (2–4). SUD in patients with MVP may stem from
ventricular ﬁbrillation (VF) (4,5), but the exact etiology and
risk predictors of SUD in MVP are elusive (6). Although
single-leaﬂet MVP is present in 2.4% of the general
Abbreviations
and Acronyms
LQTS = long QT syndrome
MVP = mitral valve prolapse
OHCA = out-of-hospital
cardiac arrest
PVC = premature ventricular
contraction
SCD = sudden cardiac death
SUD = sudden unexpected
death
VF = ventricular ﬁbrillation
VT = ventricular tachycardia
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223population (7), the reported annual rate of SUD in patients
with MVP is exceedingly low (3,4). Thus, identifying the
small subset of patients with MVP who may be at increased
risk for sudden death is difﬁcult. There are case reports and
small case series linking SUD andOHCA toMVP, especially
in younger female patients with complex ventricular ectopic
activity (2,6,8–19).
The prevalence of MVP and ventricular ectopic activity in
patients with unexplained OHCA is unclear. Furthermore,
there are only a few small reports comparing patients with
OHCA with and without mitral valve abnormalities. We
report on the prevalence of MVP in a cohort of patients with
unexplained OHCA and compare the clinical phenotype of
patients with and without MVP.Methods
Study cohort and study design. For this institutional
review board–approved study, 2 investigators (C.S.S.,
M.E.F.) retrospectively reviewed the electronic medical
records of 1,200 consecutive patients seen in the Mayo
Clinic’s Long QT Syndrome/Genetic Heart Rhythm Clinic
between July 2000 and December 2009. All patients who had
histories of unexplained OHCA with documented cardio-
vascular collapse from ventricular tachycardia (VT) or VF
that required deﬁbrillation to restore sinus rhythm were
included. In all patients, the etiology of OHCA remained
elusive after detailed review of histories, previous medical
records, and additional investigations. Patients were excluded
if: 1) VF or VT was not documented; 2) VT was present
without cardiovascular collapse; 3) family history was positive
for channelopathy, cardiomyopathy, SUD, or OHCA; or 4)
OHCA was attributable to a cardiac channelopathy, Wolff-
Parkinson-White syndrome, cardiomyopathy (including
arrhythmogenic right ventricular cardiomyopathy), coronary
artery disease, congenital coronary artery anomalies, elec-
trolyte derangements, or drugs or medications or was
preceded by known depressed left ventricular ejection frac-
tion. None of the included patients had any noncardiac
syndromic features or documented family histories of MVP.
Clinical testing. Besides the review of the outside medical
records after OHCA, all patients underwent standard inves-
tigations, including transthoracic echocardiography (20) and
12-lead electrocardiography. All patients had normal resting
corrected QT intervals, and none had electrocardiographic
features suggestive of Brugada syndrome or arrhythmogenic
right ventricular dysplasia. Most patients underwent addi-
tional testing on a discretionary basis, guided by the circum-
stances of the OHCA and depending on the extent of the
primary evaluation, including 24- or 48-h Holter recording,
genetic testing for channelopathies, provocative intravenous
procainamide or epinephrine testing, exercise stress testing,
cardiac computed tomography, cardiac magnetic resonance
imaging, electrophysiology study, or coronary angiography.
Overall, 20 patients (83%) had genetic testing for chan-
nelopathies ordered during the course of their primaryevaluations or performed as part
of their Mayo Clinic evaluations
(Table 1). Seventeen patients
were tested for mutations in the
most common long-QT syn-
drome (LQTS)–associated genes
by either the Mayo Clinic
Windland Smith Rice Sudden
Death Genomics Laboratory or
a commercially available LQTS
test (21). LQTS genetic testing
was performed when a diagnosis
of LQTS was considered by the
referring physicians. After expert
review at our institution, LQTS
diagnosis was considered unlikely in this cohort of patients
on the basis of detailed clinical histories; normal corrected
QT intervals during the resting state, exercise, and recovery;
negative results on epinephrine testing when indicated; and
negative genetic test results (22,23).
Genetic testing done at the discretion of the referring
physicians speciﬁcally for deleterious mutations within
cardiac sodium channel and/or ryanodine receptor gene
for suspected catecholaminergic polymorphic VT yielded
negative results in 9 patients.
Signiﬁcant coronary artery disease and presence of
anomalous coronary arteries were excluded on coronary
angiography and/or noninvasive imaging (computed tomo-
graphy or cardiac magnetic resonance). Cardiomyopathy was
excluded in part by expert review of cardiac imaging studies
showing preserved left ventricular ejection fraction (>50%)
and normal ventricular wall thickness.
Blinded to the speciﬁc clinical histories and echocardio-
graphic ﬁndings, we reviewed the 12-lead electrocardiograms
of all OHCA survivors. Ambulatory (24- or 48-h) Holter
recordings were available for the majority of patients and were
reviewed for density and site of premature ventricular
contraction (PVC) origin, type of PVC (singlets, couplets, or
triplets), and presence of VT. Complex ventricular ectopic
activity was deﬁned as the presence of PVC couplets,
ventricular bigeminy, nonsustained VT, or sustained VT. All
available 12-lead electrocardiograms were analyzed by 2
investigators (C.S.S., F.F.S.) for age-inappropriate ST-T-
segment repolarization changes, including T-wave inversion
or biphasic T waves, ST-segment depression or elevation, and
J waves.
Blinded to the details of the individual clinical histories as
well as the results of echocardiography and other tests (but
unblinded to the diagnosis of OHCA), a single investigator
(F.C.) retrospectively reviewed all echocardiograms per-
formed and conﬁrmed or revised the echocardiographic
ﬁndings. The diagnosis of MVP and grading of mitral
regurgitation from 1 (trivial) to 4 (severe) were according to
standard guidelines. MVP was deﬁned as systolic displace-
ment (>2 mm) of 1 or both mitral valve leaﬂets into the
left atrium beyond the plane of the mitral annulus in a
Table 1 Demographics of OHCA Cohort (n ¼ 24)
Demographic OHCA Cohort Bileaﬂet MVP No MVP p Value*
n 24/1,200 (2%)jj 10/24 (42%) 14/24 (58%) d
Age at sentinel event (yrs) 32  15 (median
33.5; range: 5–60)
33  16 (median 34.7;
range: 5–60)
32  14 (median 29.4;
range: 14–51)
0.84y
Women 16 (67%) 9/10 (90%) 7/14 (50%) 0.04
QTc interval (ms) 430  25 434  22 428  28 0.52x
Cardiac arrest as sentinel event 22/24 (92%) 8/10 (80%) 14/14 (100%) 0.16z
Activity at time of cardiac arrest 17 wakeful rest, 7 acute
emotional or physical
stress, 0 sleep
8 wakeful rest, 2 acute
emotional or physical
stress, 0 sleep
9 wakeful rest, 5 acute
emotional or physical
stress, 0 sleep
0.65z
ICD implantation 24/24 (100%) 10/10 (100%) 14/14 (100%) d
Follow-up after ICD placement (yrs) 3.8  4.1 (median 1.8;
range: 0.1–11.9)
7.2  3.5 (median 7.3;
range: 2.4–11.9)
1.4 – 2.5 (median 0.7;
range: 0.1–5.9)
0.0003y
Patients with appropriate ICD therapies 13/24 (54%) 8/10 (80%) 5/14 (36%) 0.04z
Genetic testing for channelopathies{ 20/24 (83%) 9/10 (90%) 11/14 (79%) 0.61z
LQTS types 1, 2, and 3 17/24 (71%) 9/10 (90%) 8/14 (57%) 0.18z
Isolated testing for SCN5A gene mutation 2/24 (8%) 0/10 (0%) 2/14 (14%) 0.49z
RYR2 gene mutation test 7/24 (29%) 2/10 (20%) 5/14 (36%) 0.65z
LVEF at presentation 60.3  1.6 60.5  3.1 60.2  1.7 0.92x
No. with abnormal RV size or function 0 0 0 d
RVSP by Doppler echocardiographic
estimation (mm Hg)
28.7  5.6
(range: 19–41)
28.6  6.0
(range: 23–41)
28.7  5.6
(range: 19–41)
0.95x
Mitral valve regurgitation 18/24 (75%) 10/10 (70%) 8/14 (57%) 0.02z
Mild 13/24 (54%) 5/10 (50%) 8/14 (57%) 1.00z
Moderate 4/24 (17%) 4/10 (40%) 0/14 (0%) 0.02z
Severe 1/24 (4%) 1/10 (10%) 0/14 (0%) 0.42z
ST-T repolarization changes# 16/23 (70%) 8/9 (89%) 8/14 (57%) 0.17z
Inverted/biphasic T wave 12/23 (52%) 7/9 (78%) 4/14 (29%) 0.04z
J wave 5/23 (22%) 1/9 (11%) 4/14 (29%) 0.62z
ST-segment depression > 1 mm 1/23 (4%) 1/9 (11%) 0/14 (0%) 0.39z
Values are n/N (%), mean  SD, or n (%). *Comparing bileaﬂet MVP with no MVP. yWilcoxon rank sum test. zFisher exact test. xStudent t test. jjPercent of all patients presenting to the Long QT Syndrome/
Genetic Heart Rhythm Clinic. {Genetic test results for channelopathies were negative in those who were tested. #One patient with bileaﬂet MVP had paced rhythm and was excluded from analysis of
repolarization changes.
ICD ¼ implantable cardioverter deﬁbrillator; LQTS ¼ long-QT syndrome; LVEF ¼ left ventricular ejection fraction; MVP ¼ mitral valve prolapse; OHCA ¼ out-of-hospital cardiac arrest; QTc ¼ corrected QT;
RVSP ¼ right ventricular systolic pressure; RYR2 ¼ ryanodine receptor type 2; SCN5A ¼ sodium channel.
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224parasternal long-axis view on transthoracic echocardiography,
along with thickened (maximal leaﬂet thickness >5 mm)
or myxomatous leaﬂets during diastole. When advanced
quantitative assessment of mitral regurgitation was not
available, its degree was assessed on the basis of visual esti-
mation of the regurgitant jet (7,24). Other echocardiographic
ﬁndings were noted as appropriate. Family echocardiographic
screening was not performed in this cohort of patients.
Statistical analysis. JMP version 9.0.1 (SAS Institute Inc.,
Cary, North Carolina) was used for data analysis. The
Shapiro-Wilk goodness-of-ﬁt test was used to determine the
distribution of continuous data. Normally distributed data
were compared using Student t tests. Data not normally
distributed were compared using Wilcoxon rank sum tests.
Fisher exact tests were used to compare frequency distribu-
tions between categorical groups. Statistical signiﬁcance was
taken at a p value 0.05.Results
Patient demographics. Twenty-four of the 1,200 patients
(2.0%) had “unexplained” OHCA (16 women [67%]; mean
age 32  15 years; median 33.5 years; range: 5 to 61 years;Table 1). OHCA was the sentinel event in 22 patients
(92%). All patients had normal corrected QT intervals
(mean corrected QT interval 430  25 ms), and the results
of genetic testing for LQTS were negative in the 17 patients
tested. Catecholaminergic polymorphic VT genetic test
results were negative in the 9 patients tested for that
condition, and 16 of the 24 patients had exercise stress test
results that were negative for any exercise-induced ventric-
ular ectopic activity that might suggest catecholaminergic
polymorphic VT. Ejection fractions were preserved in our
patients (mean left ventricular ejection fraction 60.3  1.6%)
and were not signiﬁcantly different between those with and
without MVP.
Echocardiography. Bileaﬂet MVP was present in 10 of
24 patients (42%), and mitral regurgitation was noted to be
mild in 5, moderate in 4, and severe in 1 (Fig. 1A, Table 1).
Of the remaining patients (58%), none had single-leaﬂet
MVP, and mitral regurgitation was either mild (n ¼ 8) or
absent (n ¼ 6). No additional signiﬁcant echocardiographic
anomalies were detected. Of those with bileaﬂet MVP, 9 of
10 (90%) were female, compared with 7 of 14 (50%) without
MVP (p ¼ 0.04). Mitral valves were morphologically normal
in all patients without MVP.
Figure 1 Triad of Sudden Death Pre-Disposing Bileaﬂet MVP Syndrome
Systolic and diastolic parasternal long-axis view of the heart demonstrating (A) bileaﬂet mitral valve thickening and mitral valve prolapse (MVP), (B) T-wave changes in the
inferior leads, and (C) frequent ventricular ectopic activity with premature ventricular beats of outﬂow tract origin alternating with papillary muscle or fascicular origin.
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225Because OHCA was the sentinel event in most patients,
it is not surprising that most of these patients did not
undergo echocardiography before their sentinel events. One
patient had echocardiographically documented bileaﬂet MVP
51 months before the sentinel event. Another patient with
bileaﬂet MVP underwent echocardiography 5 months before
the sentinel event, but the results were unavailable for review.
ST-T repolarization changes. Age-inappropriate ST-T
repolarization electrocardiographic changes were observed
in 16 of 24 survivors (67%) of OHCA (Table 1). Onepatient with bileaﬂet MVP had paced ventricular rhythm
and was excluded from analysis of repolarization changes.
T-wave abnormalities (inverted or biphasic T waves) were
more frequent in those with bileaﬂet MVP (7 of 9 [77.8%])
compared with those without MVP (4 of 14 [29%]) (p¼ 0.04)
(Fig. 1B). The abnormalities were usually noted in the
inferior leads. However, the frequency of J waves or
ST-segment depression >1 mm was not signiﬁcantly
different between the 2 groups. ST-segment elevation and
pathological Q waves were absent in all patients.
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226Holter results. The prevalence of ventricular ectopic
activity in the OHCA survivor cohort is summarized in
Table 2. Ambulatory monitoring results were available for
19 of 24 of the OHCA survivors (79%), including 9 of the
10 with bileaﬂet MVP and 10 of the 14 without MVP.
Patients with bileaﬂet MVP had a signiﬁcantly higher
burden of ventricular ectopic activity (median 67 vs.
23 PVCs/h, p ¼ 0.002) and more frequent ventricular
bigeminy (9 of 9 [100%] vs. 1 of 10 [10%], p < 0.0001) and
nonsustained or sustained VT (7 of 9 [78%] vs. 1 of
10 [10%], p ¼ 0.006) compared with patients without MVP
(Figs. 2A and 2B, Table 2). In 9 patients (7 with bileaﬂet
MVP), we noted PVC conﬁgurations of outﬂow tract origin
alternating with papillary muscle or fascicular origin
(Fig. 1C). The outﬂow tract PVCs always originated from
the left ventricular outﬂow tract and in some cases arose
from both the left and right ventricular outﬂow tracts.
OHCA survivors with bileaﬂet MVP more commonly
demonstrated such alternating PVC conﬁgurations than
those without MVP (7 of 9 [78%] vs. 2 of 10 [20%], logistic
regression odds ratio: 14; 95% conﬁdence interval: 1.5 to
127; p ¼ 0.02) (Table 2, Fig. 2C).
Electrophysiological study. Three patients with bileaﬂet
MVP underwent invasive electrophysiological assessment of
ventricular arrhythmias at our institution. Intracardiac
echocardiography, pace mapping, and activation mapping
were used. Frequent PVCs of multiple conﬁgurations
correlating with clinically documented arrhythmias were
noted in all patients. The earliest site of origin was mapped
to the tips, body, or bases of either the anterior or posterior
papillary muscles. At these sites, fascicular signals preceded
the local ventricular electrogram during ventricular ectopic
activity or tachycardia. In 1 of these patients, there were
markedly abnormal regions of slowed conduction in theTable 2
Relationship of Ventricular Ectopic Activ
Ambulatory Holter Monitoring (n ¼ 19)
Variable Bileaﬂet
PVCs 9/
Ventricular ectopic activity burden (PVCs/h) 67
NSVT/sustained VT 7/
Polymorphic VT 4/
Episodes of NSVT per h 0.3
Bigeminal PVCs 9/
Bigeminal PVCs per h 0.4 (
Ventricular couplets per h 3.0
Alternating papillary muscle/outﬂow tract PVCsx 7/
Other sites of PVC origin
RV free wall 1/
RV midcavity 2/
LV midcavity 2/
Fascicle/papillary muscle alone 0
Multiform PVCs 1/
Values are n/N (%) or median (range). *Comparing bileaﬂet MVP with no M
morphologies: originating from outﬂow tract (RV outﬂow tract alone, n ¼ 0;
papillary muscle or fascicle (n ¼ 9).
LV ¼ left ventricular; NSVT ¼ nonsustained ventricular tachycardia;
VT ¼ ventricular tachycardia; other abbreviations as in Table 1.surrounding myocardium. Two of these patients had PVCs
or VT arising additionally from the left ventricular outﬂow
tract and 1 from the septal aspect of the mitral annulus.
Follow-up. All survivors had implantable cardioverter-
deﬁbrillators placed after their OHCA. After a median
1.8 years (range: 0.1 to 11.9 years) of follow-up, 13 of 24
(54%; 10 women; median age at diagnosis 39 years; range:
5 to 51 years), patients had received appropriate VF-
terminating implantable cardioverter-deﬁbrillator therapy,
whereas 11 of 24 (46%; 6 women; median age at diagnosis
22 years; range: 14 to 61 years) patients have not yet had VF
recurrence. Only bileaﬂet MVP was associated with VF
recurrences requiring implantable cardioverter-deﬁbrillator
therapy on follow-up (logistic regression odds ratio: 7.2;
95% conﬁdence interval: 1.1 to 48; p ¼ 0.028) (Table 3).
Discussion
We observed an increased prevalence of female gender and
bileaﬂet MVP in a cohort of young patients successfully
resuscitated from idiopathic OHCA. More than 40% of
these OHCA survivors had bileaﬂet MVP, compared with
the 2.4% population prevalence of MVP for which the
majority is single-leaﬂet prolapse (7,25). Ninety percent
(9 of 10) of those with bileaﬂet MVP in this study were
women. Compared with the estimated 13% to 17% preva-
lence of MVP in the general female population aged 20 to
39 years (26), more than half (9 of 16 [56%]) of the young
female OHCA survivors had MVP. Again, the MVP
detected was bileaﬂet in all patients, whereas the vast
majority of MVP in the general population and female-
speciﬁc prevalence estimates involves single-leaﬂet MVP.
In addition, the hourly PVC burden among our OHCA
survivors (136  208; range: 0.8 to 690) was also higherity With Bileaﬂet MVP in OHCA Survivors With
MVP (n ¼ 9) No MVP (n ¼ 10) p Value*
9 (100%) 7/7 (100%) d
(35–690) 23 (1–258) 0.002y
9 (78%) 1/10 (10%) 0.006z
9 (44%) 1/10 (10%) 0.14z
(0–7.4) 0 (0–0.1) 0.003y
9 (100%) 1/10 (10%) <0.0001y
0.05–67.6) 0 (0–0.3) 0.0003y
(0.3–26.5) 0.04 (0–1.6) 0.0015y
9 (78%) 2/10 (20%) 0.02z
9 (11%) 1/10 (10%)
9 (22%) 1/10 (10%)
9 (22%) 1/10 (10%)
/9 (0%) 1/10 (10%)
9 (11%) 0/10 (0%)
VP. yWilcoxon rank sum test. zFisher exact test. xPVCs of alternating
LV outﬂow tract alone, n ¼ 4; or RV and LV outﬂow tracts, n ¼ 5) and
PVC ¼ premature ventricular contraction; RV ¼ right ventricular;
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Figure 2 Ventricular Ectopic Activity and Bileaﬂet MVP
(A) Comparison of the burden of ventricular ectopic activity between patients with
bileaﬂet mitral valve (MV) prolapse (MVP) and those with normal MVs. (B)
Prevalence of nonsustained ventricular tachycardia (NSVT) or sustained ventricular
tachycardia (VT) between patients with bileaﬂet MVP and those with normal MVs.
(C) Frequency of premature ventricular contractions (PVCs) of alternating
conﬁgurations (outﬂow tract alternating with papillary muscle or fascicular region)
between those 2 groups.
Table 3
Association of Patient Characteristics, Ventricular
Ectopic Activity, and Bileaﬂet MVP With
Appropriate ICD Therapies on Follow-Up
Variable
Appropriate ICD
Therapies (n ¼ 13)
No Appropriate ICD
Therapies (n ¼ 11) p Value*
Age at sentinel
event (yrs)
39 (5–51) 22 (14–61) 0.30y
Women 10/13 (77%) 6/11 (55%) 0.39z
QTc interval (ms) 435  19 425  31 0.38x
Ventricular ectopic
activity burden
(PVCs/hr)
43.2 (9.7–690.3) 27.2 (0.8–258.3) 0.17y
NSVT/sustained VT 7/13 (54%) 1/6 (17%) 0.18z
Polymorphic VT 5/13 (38%) 0/6 (0%) 0.13z
Episodes of NSVT
per hour
0.1 (0–7.4) 0 (0–0.05) 0.088y
Bigeminal PVCs 8/13 (62%) 2/6 (33%) 0.35z
Bigeminal PVCs
per hour
0.08 (0–67.6) 0 (0–0.9) 0.33y
Ventricular couplets
per hour
1.1 (0–26.5) 0.1 (0–1.6) 0.10y
Alternating papillary
muscle/outﬂow
tract PVCs
6/13 (46%) 3/6 (50%) 1.00z
Bileaﬂet MVP 8/13 (62%) 2/11 (18%) 0.047z
Values are median (range), n/N (%), or mean  SD. *Comparing bileaﬂet MVP with no MVP.
yWilcoxon rank sum test. zFisher exact test. xStudent t test.
Abbreviations as in Tables 1 and 2.
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227than in the general population (mean 0.38 PVCs/h,
average <5 PVCs/h) (27). We noted an increased frequency
of complex ventricular ectopic activity including PVC
conﬁgurations of the outﬂow tract alternating with papillary
muscle or fascicular origin in OHCA survivors, speciﬁcally
patients with bileaﬂet MVP. Biphasic or inverted T waves
on electrocardiography were more frequent in our survivors
with bileaﬂet MVP (70%) compared with those without
MVP (29%). Our ﬁndings suggest that there may be a
collective sudden death–pre-disposing syndrome or pheno-
type characterized in young women with bileaﬂet MVP,
biphasic or inverted inferior T waves, and complex ventric-
ular ectopic activity with alternating outﬂow tract and
papillary muscle or fascicular conﬁgurations (Fig. 1).
Previous published reports support our ﬁndings. In a
small study of only 6 patients with OHCA diagnosed with
idiopathic VF, MVP was reported in 2 patients (33.3%)
(28). MVP was also noted in 7 of 28 (25%) (29) and 12 of
35 (34.3%) (30) patients with idiopathic VT in 2 separate
case series. These studies, however, were limited by the lack
of documentation of the exact mitral valve abnormalities,
and patients with channelopathies, cardiomyopathies, or
ischemia were not necessarily excluded.
When comparing our subset with OHCA and bileaﬂet
MVP with reported cases of SUD (Table 4) or OHCA or
malignant ventricular arrhythmias (Table 5) linked to MVP,
we note several important similarities. The reported patients
were similarly relatively young, more often female (63.2%
Table 4 Summary of SCDs Linked to MVP Reported in the English Language
SCDs
Age Range
(yrs) Women Bileaﬂet MVP
Complex Ventricular
Ectopic Activity
ST-T Repolarization
Changes on ECG
Mild or
Greater MR Ref. #
25 9–64 11/16 (68.8%) 7/10 (70%) d 9/10 (90%) d (8,42)
4 29–64 3/4 (75%) d d d d (10)
14 14–59 (27  11) 11/14 (78.6%) 11/14 (78.6%) d 2/7 (28.6%) d (38)
17 17–45 12/17 (70.6%) d 4/13 (30.8%) 6/11 (54.5%) d (11)
6 31–70 2/6 (33.3%) d d d d (3)
1 d d d d d 1/1 (100%) (40)
3 27–70 1/3 (33.3%) d d d d (4)
4 26–40 4/4 (100%) 3/4 (75%) 3/4 (75%) d d (13)
15 39  17 10/15 (67%) d d d 1/15 (7%) (14)
6 d d d d d 6/6 (100%) (43)
27 37  10 14/27 (51.9%) d d d d (15)
2 28–44 0/2 (0%) d d 2/2 (100%) d (2)
17 35 12/17 (70.6%) d d d Uncommon (16,17)
6 17–34 6/6 (100%) d d (6)
6* 8–38 4/5 (80%) 1/1 (100%) 1/1 (100%) d d (9,12,18,19,44)
Total ¼ 153 8–70 91/144 (63.2%) 22/29 (75.9%) 8/18 (44.4%) 19/30 (63.3%) 8/22 (36.4%)
Values are mean  SD or n/N (%). Studies are ordered chronologically by date of publication. *Individual case reports of sudden unexplained death (n  2) linked to MVP are grouped together and presented
at the end of the table.
ECG ¼ electrocardiography; MR ¼ mitral regurgitation; MVP ¼ mitral valve prolapse; SCD ¼ sudden cardiac death; d ¼ data were either not obtained or not provided in the primary report.
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228among patients with SUD, 72.8% among those with
OHCA or malignant ventricular arrhythmia), and bileaﬂet
MVP was common (75.9%) in patients with SUD whenever
the type of prolapse was documented explicitly. In addition,
at least mild mitral regurgitation, complex ventricular
ectopic activity, and inferolateral repolarization abnormali-
ties on electrocardiography (Tables 4 and 5) were present
in similar frequency to our OHCA cohort. However, much
of this information as well as ventricular ectopic activity
burden and details on diagnosing and excluding channelo-
pathies, cardiomyopathies, and ischemia were not uniformly
reported.
In our cohort, PVCs were universal among OHCA
survivors whether or not MVP was present. Given the
similar high frequency of PVCs in an MVP population (58%
to 89%), healthy controls, or in this cohort, the presence of
PVCs alone has little prognostic value (31–33). However,
OHCA survivors with bileaﬂet MVP had a higher PVC
burden compared with those without MVP. Complex
ventricular ectopic activity (speciﬁcally ventricular bigeminyTable 5 Summary of OHCA and Malignant Ventricular Arrhythmias Li
OHCA/Malignant
Ventricular Arrhythmias
Age Range
(yrs) Women Bileaﬂet MVP
7 21–61 5/7 (71.4%) d
4 23–70 3/4 (75%) d
2 d d d
5 29–47 3/5 (60%) d
9 (2 SUDs) 22–66 7/9 (77.8%) d
7 28–90 5/7 (71.4%) d
1 54 1/1 (100%) 1/1 (100%)
Total ¼ 35 21–90 24/33 (72.8%) 1/1 (100%)
Values are range or n/N (%). Studies are ordered chronologically by date of publication.
SUD ¼ sudden unexplained death; VE ¼ ventricular ectopic activity. Other abbreviations as in Tablesand/or nonsustained or sustained VT) was more frequent in
patients with MVP than those without. Furthermore, the
clinical proﬁle of our OHCA survivors with MVP appears
to be distinct from a general population of patients with
single-leaﬂet MVP; notably, our cohort demonstrates a
higher frequency of female gender (90% vs. approximately
50%) (7), bileaﬂet prolapse (100% vs. 10%) (25), and non-
sustained or sustained VT (78% vs. 18.7%) (4,33).
The exact role of PVC conﬁgurations of the outﬂow tract
alternating with papillary muscle or fascicular origin in the
genesis of VF is unclear. In a prior study of 10 patients with
MVP (3 with bileaﬂet MVP), PVCs originated from the
posterobasal region of the left ventricle in 6. It is possible
that PVCs originating close to the prolapsing mitral valve
leaﬂet (basal left ventricle or left ventricular outﬂow tract
region) and adjacent structures such as the left ventricular
papillary muscles and fascicles in an alternating fashion
could be potential VF triggers (34).
The reason for outﬂow tract ectopic activity in general in
this population is not fully understood from our study.nked to MVP Reported in the English Language
Complex VE
ST-T Repolarization
Changes on ECG
Mild or
Greater MR Ref. #
2/7 (28.6%) 4/7 (57.1) d (45)
4/4 (100%) Very common d (37)
d d d (46)
d d d (47)
d d d (5)
6/7 (85.7%) 2/7 (28.6%) 0/7 (0%) (2)
d d d (48)
12/18 (66.7%) 6/14 (42.9%) 0/7 (0%)
1 and 4.
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229Because outﬂow tract ectopic activity is the most common
type of ectopic activity in structurally normal hearts, this may
simply represent the second abnormality (high background
rate) in addition to the speciﬁc pathology related to the
disease (MVP and papillary muscle ectopic activity). Because
the left ventricular outﬂow tract does have a shared region
with the mitral annulus (aortic mitral continuity), and
because this site is a relatively frequent site of ectopic
activity, the ectopic activity from this region may be related
to mechanical reasons from the MVP itself. Papillary muscle
ectopic activity itself may be related to myocardium or may
have conduction system–related origin. Fascicular ectopic
activity has also been noted to occur from other locations,
including the mitral annulus and the outﬂow tract. Given
the now established relationship between fascicular ectopic
activity and triggers for VF, our patients may represent
fascicular disease arising from 2 sites in association with
bileaﬂet MVP (35,36).
The estimated rate of SCD in patients with MVP is 16 to
41 per 10,000 per year (0.2% to 0.4% per year) on the basis
of prospective data (3,4), and the SCD is attributed to VF
(4,5). However, the relationship between MVP and VF in
patients without other heart conditions has not been
elucidated. Traction on papillary muscles, endocardial fric-
tion lesions, coronary microemboli from platelet-ﬁbrin
aggregates adjacent to the prolapsing mitral valve leaﬂet,
transient ischemia due to mechanical alterations in coronary
blood ﬂow, and increased autonomic tone are proposed
mechanisms (37–39). Ectopic impulse initiation in the
mitral valve leaﬂet muscle bundles, secondary to stretching
or catecholamine exposure, is also plausible (37). Some have
proposed that MVP-related SCD may be linked to the
hemodynamic and arrhythmogenic consequences of mitral
regurgitation, as opposed to being secondary to the MVP
itself (40).
Nishimura et al. (3) identiﬁed a redundant mitral valve as
a risk factor for adverse outcomes in a prospectively followed
asymptomatic or minimally symptomatic cohort of patients
with MVP (n ¼ 237). All 6 SCDs in that series occurred
among the 97 patients with redundant mitral valves.
Campbell et al. (41) identiﬁed a high-risk subset (n ¼ 8)
with inferolateral ST-T repolarization changes among
17 patients with clinically apparent, echocardiographically
documented MVP. VT or VF was seen exclusively in 4 of
8 patients (50%) in this high-risk subset with MVP. Similar
electrocardiographic changes were also reported in some
MVP-linked cases of SUD and OHCA (Tables 4 and 5).
In our cohort of survivors with bileaﬂet MVP, biphasic or
inverted T waves on electrocardiography were present in
70%, usually in the inferior leads.
Study limitations. This study was limited by its retro-
spective design, a relatively small population of patients with
OHCA, and a potential for referral bias. A detailed analysis
of the exact interaction between different variables was
precluded by limited numbers. Because of the retrospective
design, it cannot be determined whether the reportedechocardiographic ﬁndings, including bileaﬂet MVP, pre-
dated the OHCA.
Conclusions
In this young cohort of survivors with documented OHCA,
we identiﬁed a potentially “malignant” MVP–ventricular
arrhythmia phenotype. It is characterized by young women
with bileaﬂet MVP, biphasic or inverted T waves in the
inferior leads, and frequent complex ventricular ectopic
activity with documented ventricular bigeminy or VT as well
as PVC conﬁgurations of outﬂow tract alternating with
papillary muscle or fascicular origin. A new approach to
prospectively identify this “malignant” subset of patients is
warranted.
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